Multicenter observational cohort study of endoscopic band ligation without resection of small-sized subepithelial tumours of the digestive tract (Banding-SET): a clinical protocol.
Gastrointestinal Endoscopy 2023 May 31
BACKGROUND AND AIMS: Endoscopic band ligation (EBL) without resection combined with a single-incision needle-knife (SINK) biopsy may have a positive impact on small gastrointestinal subepithelial tumor (SET) management, but it needs to be tested. The aim was to evaluate the feasibility of this strategy in small-sized SET.
METHODS: This prospective multicenter observational cohort study in 7 centers included patients with SETs ≤15mm (confirmed by endoscopic ultrasound (EUS)) between March 2017 and March 2020. The primary outcome was 4 weeks clinical success defined as complete SET disappearance at EUS control. Secondary outcomes were long-term (1 year) clinical success, technical difficulty level, clinical impact, yield pathology, and safety.
CLINICALTRIALS: gov, NCT03247231.
RESULTS: Some 273 patients were screened, and 122 (62.3% women, mean age 60.9±13.2) were included with SET (mean size, 9mm±2.8; gastric location 77%, superficial layer-dependence 63%). Primary endpoint was achieved in 73.6% (95%CI 64.8-81.2). At 1-year follow-up, success rate was 68.4% (95%CI 59.1-76.8). A favorable clinical impact was observed in 97 cases (79.5%, 95%CI 71.3-86.3). Pathology diagnosis was known in 70%. Potentially malignant lesions were present in 24.7%. Related-adverse events rate was 4.1% (95%CI 1.3-9.3; all mild, n=2 bleeding, n=2 abdominal pain). On multivariable analysis, ≤10mm SET group was associated with a greater success rate (1-year, 87%; RR5.07[95%CI 2.63 - 9.8]) and clinical impact rate (92.7%; RR6.15 [95%CI 2.72 - 13.93].
CONCLUSIONS: EBL plus SINK-biopsy seems to be feasible, and safe, and it may offer a favorable clinical impact in small-sized SETs. Concretely, SETs ≤10mm are the best candidates.
METHODS: This prospective multicenter observational cohort study in 7 centers included patients with SETs ≤15mm (confirmed by endoscopic ultrasound (EUS)) between March 2017 and March 2020. The primary outcome was 4 weeks clinical success defined as complete SET disappearance at EUS control. Secondary outcomes were long-term (1 year) clinical success, technical difficulty level, clinical impact, yield pathology, and safety.
CLINICALTRIALS: gov, NCT03247231.
RESULTS: Some 273 patients were screened, and 122 (62.3% women, mean age 60.9±13.2) were included with SET (mean size, 9mm±2.8; gastric location 77%, superficial layer-dependence 63%). Primary endpoint was achieved in 73.6% (95%CI 64.8-81.2). At 1-year follow-up, success rate was 68.4% (95%CI 59.1-76.8). A favorable clinical impact was observed in 97 cases (79.5%, 95%CI 71.3-86.3). Pathology diagnosis was known in 70%. Potentially malignant lesions were present in 24.7%. Related-adverse events rate was 4.1% (95%CI 1.3-9.3; all mild, n=2 bleeding, n=2 abdominal pain). On multivariable analysis, ≤10mm SET group was associated with a greater success rate (1-year, 87%; RR5.07[95%CI 2.63 - 9.8]) and clinical impact rate (92.7%; RR6.15 [95%CI 2.72 - 13.93].
CONCLUSIONS: EBL plus SINK-biopsy seems to be feasible, and safe, and it may offer a favorable clinical impact in small-sized SETs. Concretely, SETs ≤10mm are the best candidates.
Full text links
Get seemless 1-tap access through your institution/university
For the best experience, use the Read mobile app
Read by QxMD is copyright © 2021 QxMD Software Inc. All rights reserved. By using this service, you agree to our terms of use and privacy policy.
You can now claim free CME credits for this literature searchClaim now
Get seemless 1-tap access through your institution/university
For the best experience, use the Read mobile app